Venetoclax▼ (Venclyxto): Updated recommendations on tumour lysis syndrome (TLS) in CLL patients

Fatal cases of TLS have been observed even in patients receiving the lowest dose used in the dose-titration schedule. Strict adherence to dose titration and TLS risk minimisation measures as outlined in the SPC is required for all patients. Patient alert cards will be provided.

SPS commentary:

Patient alert cards, which will be distributed to prescribing haematologists, should be given to each patient treated with venetoclax. This will include the importance of hydration and a list of symptoms of TLS which should prompt the patient to seek immediate medical attention in case of their occurrence.

Abbvie